The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 13 April 2026•Updated 14 April 2026•

1 min read

Analysts Project Massive Upside for Omeros and Assertio Amid Broad Earnings Revisions

Key Facts

1The average analyst price target for Encompass Health (EHC) indicates a potential upside of 31.7%.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: The story was updated to include massive new price targets for Omeros, Assertio, Nurix, Extreme Networks, and SM Energy, expanding the bullish outlook beyond the initial healthcare focus.

Wall Street analysts have significantly expanded their bullish projections, with Omeros (OMER) now leading the group with a staggering potential upside of 266.7% based on average price targets. The positive sentiment extends to other biotech players, including Assertio (ASRT) and Nurix Therapeutics (NRIX), which are projected to rally by 115.1% and 85.8% respectively. This wave of optimism has also reached the technology and energy sectors, with Extreme Networks (EXTR) seeing a 32.4% upside target and SM Energy (SM) positioned for a 27.9% gain. These new projections build upon previous positive outlooks for Encompass Health and Relmada Therapeutics, all supported by a consistent trend of upward earnings per share (EPS) revisions. Analysts view these broad-based estimate hikes as a reliable indicator of strengthening financial health across multiple industries, positioning these stocks as key targets for growth-oriented investors.